INTRODUCTION {#S1}
============

Persistent HIV-1 infection is due to its capacity to integrate into the host cell DNA where the provirus may persist in a latent form. Antiretroviral treatment (ART) controls viral replication but cannot eliminate this latent reservoir ([@R14]; [@R35]). A very small number of these residual, latently infected cells may be sufficient to refuel viral replication and replenish the reservoir if ART fails or is interrupted ([@R16]). Resting memory CD4+ T cells, preferentially stem cell memory ([@R5]) and central memory ([@R7]), constitute the main reservoir for HIV-1. This reservoir is established very early after infection ([@R40]), but its size is quite low in patients on ART. It has been recently estimated between 10 and 100 replication-competent latent provirus per million resting CD4+ T cells ([@R17]).

In latent state, HIV-1 persists unscathed by immune response or ART, but T cell activation resumes viral production. Among the inducers of HIV reactivation are T cell receptor (TCR) activation and inflammatory cytokines such as tumor necrosis factor (TNF) or interleukin 6 (IL-6) ([@R8]), whereas the role of common gamma chain (γc) cytokines such as IL-7 and IL-2 is controversial ([@R3]). IL-7 is crucial for T cell development and homeostasis and participates in survival and maintenance of memory CD4+ T cells ([@R21]). During HIV infection, increased levels of IL-7 can be detected, but they are not sufficient to maintain T cell homeostasis and CD4+ count progressively declines ([@R28]). Several clinical trials with IL-7 have been performed in HIV-infected individuals with the goal of increasing the number and function of lymphocytes, particularly memory cells ([@R24]; [@R25]; [@R34]; [@R20]). When tested as a potential anti-latency drug, IL-7 produced T cell proliferation plus low-level viral reactivation ([@R3]), failing to deplete the viral reservoir and even increasing, at least transiently, the proviral load ([@R20]; [@R34]).

HIV-1 infects and replicates in activated CD4+ lymphocytes, but once the drivers of T cell activation diminish, resting CD4+ lymphocytes are mostly non-permissive for HIV-1 replication. This is largely due to the absence of essential transcription factors such as NF-κB and NF-AT ([@R9]) and to the SAMHD1 protein ([@R13]; [@R2]). SAMHD1 is a key regulator of cell-cycle progression and a major viral restriction factor that blocks early reverse transcription of HIV-1 by depleting the intracellular dinucleotide triphosphate (dNTP) pool ([@R23]). It has been proposed that HIV restriction of SAMHD1 can also be related with degradation of viral RNA through its RNase activity ([@R30]), but this concept remains controversial ([@R33]). The function of SAMHD1 is regulated through the phosphorylation of threonine 592 (T592) by cyclin A2/Cdk1, an event that is induced by T cell activation and that renders the cells susceptible to infection by HIV-1 ([@R10]). The accessory protein Vpx of HIV-2 and the simian immunodeficiency virus (SIV) target SAMHD1 for ubiquitination and proteasomal degradation ([@R22]). As HIV-1 does not encode Vpx, it remains sensitive to SAMHD1-mediated restriction until T cells receive an activation signal. We evaluated the effect of γc-cytokines such as IL-2 and IL-7 and determined that they induced SAMHD1 phosphorylation in CD4+ T cells, promoting susceptibility to HIV-1 infection. Moreover, as tyrosine kinases are essential during T cell activation driven by IL-7 ([@R19]), we observed that the tyrosine kinase inhibitor dasatinib interfered with SAMHD1 phosphorylation mediated by IL-7, which preserves its antiviral activity and identifies this factor as a potential therapeutic target.

RESULTS {#S2}
=======

TCR-Mediated Activation and Homeostatic Stimuli Such as IL-2 and IL-7 Induced the Phosphorylation of SAMHD1 at T592 in Human CD4+ T Cells {#S3}
-----------------------------------------------------------------------------------------------------------------------------------------

Stimuli such as TCR-mediated activation and γc-cytokines were analyzed to determine their role in SAMHD1 phosphorylation at T592 in human primary CD4+ T cells. When CD4+ lymphocytes were treated with anti-CD3/CD28 for 5 days, SAMHD1 phosphorylation initiated after 1 day of TCR-mediated activation ([Figure 1A](#F1){ref-type="fig"}, left), reaching a peak at day 2 that rapidly decayed. Simultaneous treatment with IL-2 permitted a sustained SAMHD1 phosphorylation that remained constant for at least 5 days ([Figure 1A](#F1){ref-type="fig"}, right). Treatment with IL-2 or IL-7 only induced SAMHD1 phosphorylation at day 3, which was sustained for at least 5 days ([Figure 1B](#F1){ref-type="fig"}). A dose-response experiment ([Figure 1B](#F1){ref-type="fig"}, bottom) did not show significant difference between treatments with low (1 nM) or high (10 nM) concentrations of IL-7. SAMHD1 phosphorylation induced by IL-2 or IL-7 was quite stable as it persisted for at least 48 hr after removing the cytokines from the culture medium ([Figure 1C](#F1){ref-type="fig"}, lanes 6 and 7). At the doses employed, IL-2 and IL-7 caused T cell proliferation after 10 days of treatment (Figure S1). Treatment of CD4+ T cells with chemokines CXCL9, CXCL10, or CXCL12 did not induce SAMHD1 phosphorylation ([Figure 1D](#F1){ref-type="fig"}, lanes 5 and 6). The expression of total SAMHD1 was not modified by the addition of any stimuli to the culture.

IL-2 and IL-7 Induced Reverse Transcription and Proviral Integration in CD4+ T Cells {#S4}
------------------------------------------------------------------------------------

To determine the role of IL-2 and IL-7 in HIV-1 reverse transcription and proviral integration, primary CD4+ T cells were treated with IL-2 or IL-7 for 5 days and then infected with X4-tropic NL4-3_Renilla luciferase strain and cultured for 5 additional days. Viral reverse transcripts (RTs) were analyzed by qPCR 5 hr post-infection. Low levels of early and late RT were induced by IL-2 treatment, whereas IL-7 induced an average 13-fold increase in early RT and 43-fold increase in late RT, compared to IL-2 (p \< 0.001; [Figure 2A](#F2){ref-type="fig"}). Both cytokines increased two long terminal repeat (2-LTR) circles and proviral integration, but IL-7 was more efficient as it induced an average 2-fold increase in the number of 2-LTR circles ([Figure 2B](#F2){ref-type="fig"}) and 19-fold increase in proviral integration as compared to IL-2 ([Figure 2C](#F2){ref-type="fig"}). Similar increases were obtained with R5-tropic strains (data not shown) and when a wild-type NL4.3 viral clone carrying the *nef* gene was used (Figures S2A--S2C). Treatment with CXCL9/CXCL10 chemokines enhanced IL-2-induced viral integration 27-fold (p \< 0.01), whereas simultaneous treatment with CXCL9/CXCL10 enhanced integration induced by IL-7 only an average of 2.2-fold (p \< 0.05; [Figure 2D](#F2){ref-type="fig"}).

Two lines of evidence suggest that IL-7 function was mediated through SAMHD1. First, overexpression of T592A SAMHD1, a phosphorylation-resistant mutant, decreased IL-2- and IL-7-mediated infection when transfected in resting CD4 lymphocytes before cytokine activation ([Figure 2E](#F2){ref-type="fig"}). Second, pretreatment with VLP-Vpx reduced IL7-mediated enhancement of infection of resting CD4 lymphocytes with HIV-cytomegalovirus (CMV)-GFP (Figure S2D).

LTR- and NF-κB-Dependent Activation in CD4+ T Cells Treated with IL-2 or IL-7 {#S5}
-----------------------------------------------------------------------------

The ability of IL-2 and IL-7 to establish latent proviral integration was determined in primary CD4+ T cells treated with IL-2 or IL-7 for 5 days and infected with NL4-3_Renilla luciferase strain for 5 additional days. Phorbol 12-myristate 13-acetate (PMA) added 18 hr before cell collection produced an average 14-fold and 17-fold increase in viral transcription in cells treated with IL-2 or IL-7 (p \< 0.001), respectively ([Figure 3A](#F3){ref-type="fig"}). Treatment with PMA did not increase proviral integration in CD4+ T cells treated with IL-7 (Figure S3).

The effect of IL-2 or IL-7 on HIV-1 transcription was also analyzed in CD4+ T cells treated with IL-2 or IL-7 for 5 days and then nucleofected with luciferase expression vectors under the control of the HIV-1-LTR (pLTR-LUC) or three copies of the NF-κB consensus (p3KB-LUC). Two hours after nucleofection, cells were incubated with PMA and cultured for 18 hr. Both IL-2 and IL-7 barely activate LTR- or NF-κB-dependent transcription that was strongly increased by PMA treatment (p \< 0.001; [Figure 3B](#F3){ref-type="fig"}).

SAMHD1 Was Preferentially Phosphorylated in Memory CD4+ T Lymphocytes of HIV-Infected Patients Included in the ACTG 5214 Study Who Received a Single Dose of IL-7 {#S6}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

To confirm that IL-7 could phosphorylate SAMHD1 in vivo, sub-populations of CD4+ lymphocytes from nine patients enrolled in the ACTG 5214 study ([@R34]) were analyzed by flow cytometry. In this study, patients were treated with a single subcutaneous dose of rhIL-7 with doses ranging from 3 to 30 microg/kg. After selection of living cells (Figure S4), combination of CCR7 and CD45RA markers allowed characterization of naive (CCR7^+^CD45RA^+^), central memory (CCR7^+^CD45RA^−^), transitional and effector memory (CCR7^−^CD45RA^−^), and terminally differentiated (CCR7^−^CD45RA^+^) CD4+ lymphocytes. SAMHD1 phosphorylation significantly increased an average 8.0% in central memory cells (p \< 0.05) and 7.0% in effector memory cells (p \< 0.05) 4 days after the single injection of rhIL-7 ([Figure 4](#F4){ref-type="fig"}).

Dasatinib Blocked IL-7-Mediated Reverse Transcription and Proviral Integration {#S7}
------------------------------------------------------------------------------

It has been described that γc-cytokines activate pathways that involve tyrosine kinases ([@R19]). Therefore, primary CD4+ lymphocytes were simultaneously treated for 5 days with IL-7 and dasatinib, an inhibitor of tyrosine kinases---currently used in the treatment of chronic myeloid leukemia ([@R11]). Dasatinib has been described to inhibit HIV-1 replication at a concentration of 75 nM ([@R29]), and we demonstrated that, at this concentration, it strongly interfered with SAMHD1 phosphorylation induced by IL-7 ([Figure 5A](#F5){ref-type="fig"}). As a result, dasatinib interfered with IL-7-mediated viral reverse transcription ([Figure 5B](#F5){ref-type="fig"}) and with proviral integration ([Figure 5C](#F5){ref-type="fig"}).

DISCUSSION {#S8}
==========

Among the mechanisms for HIV persistence, factors that extend lifetime and homeostatic proliferation of infected cells are of paramount importance ([@R12]). In this context, IL-7 is crucial for T cell development and homeostasis and also participates in the survival and maintenance of memory CD4+ lymphocytes ([@R21]). IL-7 was first reported to increase HIV replication in peripheral blood mononuclear cells (PBMCs) of infected individuals ([@R36]), in resting CD4+ lymphocytes from patients on ART ([@R39]), and in chronically infected human cells ([@R32]). As a result, IL-7 was originally proposed as a potential anti-latency agent. Early clinical trials of IL-7 administration were associated with an increased frequency of ''blips'' of HIV RNA in plasma among HIV-infected patients who were receiving suppressive ART ([@R18]; [@R25]). But although IL-7 can activate phosphatidylinositol 3-kinase (PI3K) pathways ([@R38]), we and others determined that NF-κB activity was only slightly increased in CD4+ lymphocytes treated with IL-7 and is not sufficient to reverse viral latency ([@R3]). Later, it was demonstrated that IL-7 may contribute to the maintenance of HIV reservoirs via homeostatic proliferation ([@R7]). In fact, administration of IL-7 to HIV-infected patients induced expansion of CD4+ lymphocytes and increased HIV DNA copy numbers ([@R20]; [@R34]).

Because γc-cytokines promote the T lymphocytes cell cycling and division and because SAMHD1 is regulated by cyclins ([@R10]), we hypothesized that γc-cytokines might also regulate SAMHD1 activity, leading to an increased susceptibility to HIV-1 infection. We evaluated the effect of IL-2 and IL-7 on SAMHD1 antiviral activity and determined that both cytokines induced SAMHD1 phosphorylation in primary CD4+ lymphocytes, thereby eliminating its antiviral activity. Consequently, IL-7 promoted successful reverse transcription and subsequent proviral integration more efficiently than IL-2. This effect was mediated through SAMHD1 as demonstrated by the use of SAMHD1 T592A mutant and VLP-Vpx, which reduced the IL7-mediated enhancement of resting CD4 lymphocytes infection. However, because IL-2 and IL-7 produced a similar pattern of SAMHD1 phosphorylation, an additional mechanism should be contributing to the higher efficiency of IL-7. It has been described that actin polymerization dynamics driven by certain chemokines influence different steps of the pre-integration process ([@R41]). Accordingly, as it has been described ([@R6]) that treatment with chemokines CXCL9 and CXCL10, among others, promote post-integration latency, we tested their impact in our model. When CD4+ T cells were treated with IL-2 and IL-7 together with CXCL9/CXCL10, stronger integration in IL-2-cultured lymphocytes was found. However, the impact of chemokine treatment on IL-7 enhancement of proviral integration was lower, suggesting that IL-7 could stabilize or modify actin dynamics as chemokines do. Furthermore, as γc-cytokines are poor inducers of NF-κB and NFAT, they might be contributing to the establishment of latent reservoirs. In fact, HIV-1 expression was incomplete in CD4+ lymphocytes infected in vitro in the presence of IL-2 or IL-7 as it was further increased with PMA. Thus, although IL-7 efficiently promoted integration, latency persisted until a stronger T cell activation signal was received. TCR-mediated activation induced faster SAMHD1 phosphorylation, which occurs at day 1 after stimulation, but this phosphorylated form rapidly decayed at day 3. On the other hand, IL-2 and IL-7 were slower to induce SAMHD1 phosphorylation, but they induced a more-stable phosphorylation that was maintained even after the stimuli were removed. This suggested that SAMHD1 phosphorylation by TCR-mediated activation or homeostatic cytokines occurred through different mechanisms.

Recent structural work has shown that homotetrameric conformation of SAMHD1 is dependent on diguanosine triphosphate (dGTP) binding, allowing a more-stable interaction with the substrate. Mutations of dGTP-binding residues in the allosteric site affect tetramer formation, dNTPase activity, and HIV-1 restriction ([@R42]). It would be important to study whether SAMHD1 phosphorylation at T592 by IL-2 and IL-7 results in decreased tetramer formation. Actually, the total amount of SAMHD1 is not modified by IL-2 or IL-7 treatment, pointing to the generation of full inactive SAMHD1 in the absence of protein degradation, an event that could be related with impairment of multimeric complexes formation due to SAMHD1 phosphorylation.

To assess the effect of IL-7 on SAMHD1 phosphorylation in vivo, we analyzed PBMCs from subjects enrolled in the ACTG 5214 trial, who received a single injection of rhIL-7 ([@R34]). A significant increase in SAMHD1 phosphorylation was observed at day 4 in central and effector memory CD4+ lymphocytes from these patients, which was in accordance with the peak of SAMHD1 phosphorylation observed in vitro after 4 days of IL-7 activation. A sharp increase in cycling ---measured by Ki67 expression---has been described in these patients at day 4 after IL-7 treatment ([@R7]; [@R34]), which strongly correlates with our observed induction of SAMHD1 phosphorylation. Our own data confirm ([@R31]) that, in healthy donors, less than 2% of CD4 lymphocytes from peripheral blood display phosphorylated SAMHD1. Basal levels of phosphorylated SAMHD1 in ACTG 5214 patients were higher and could be related to the high level of immune activation described in HIV-infected patients even in the presence of ART. Actually, ACTG 5214 patients displayed high levels of lymphocyte activation as assessed by CD38/HLA-DR expression ([@R7]; [@R34]).

It has been proposed that the persistence of the viral reservoir mostly occurs through homeostatic proliferation induced by γc-cytokines such as IL-7 ([@R7]). In fact, IL-7 therapy promotes CD4+ expansion in HIV-infected patients on ART ([@R25]) while concurrently expanding the pool of provirus-containing CD4+ lymphocytes ([@R25]; [@R37]; [@R20]). Our findings show that IL-7 induced SAMHD1 phosphorylation in CD4+ lymphocytes, which supported the notion that this cytokine has a role not only in reservoir expansion but also in increasing the infectivity of memory cells, leading to HIV integration and reservoir replenishment. Accordingly, impeding SAMHD1 phosphorylation may represent a valuable target to increase restriction to HIV-1 infection in CD4+ lymphocytes. Because γc-cytokines activate JAK/STAT pathways through tyrosine phosphorylation, we assessed whether the tyrosine kinase inhibitor dasatinib also prevented SAMHD1 phosphorylation. We demonstrate that inhibition of SAMHD1 phosphorylation by dasatinib strongly decreased HIV reverse transcription and integration. Consequently, tyrosine-kinase inhibitors may represent potential candidates to be used as adjuvants to ART, in particular in primary infection when viral reservoirs are established.

In conclusion, we propose a model in which γc-cytokines seed and replenish the reservoir during suboptimal T cell activation. In this model, IL-7 and IL-2 would promote SAMHD1 phosphorylation, making CD4+ lymphocytes more susceptible to HIV-1 infection by facilitating reverse transcription and, subsequently, proviral integration. However, these γc-cytokines are weak inducers of viral transcription ([@R3]), and therefore, IL-7 and IL-2 would maintain preferentially the provirus in latency. It cannot be discarded that IL-2 and IL-7 contribute to blips or low persistent viremia that can be detected in patients on ART ([@R9]; [@R18]). Consequently, IL-7 would fulfill three essential roles in HIV-1 persistence: reservoir seeding through SAMHD1 phosphorylation, low ongoing expression via NF-κB activity, and reservoir maintenance through homeostatic proliferation. In this model, full activation of proviral transcription through TCR-mediated activation or inflammatory cytokine exposure would drive robust viral replication and CD4 depletion.

EXPERIMENTAL PROCEDURES {#S9}
=======================

Cells {#S10}
-----

PBMCs were isolated from healthy donors by Ficoll-Hypaque gradient (GE Healthcare). Primary CD4+ T cells were isolated using CD4+ T Cell Isolation Kit (Miltenyi Biotec).

Patients {#S11}
--------

Blood samples of patients treated with IL-7 belong to ACTG5214 study. This study was approved by the institutional review boards (IRBs) of all participating sites, and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki (NCT 00099671; as stated in [@R34]).

Blood from nine patients enrolled in ACTG 5214 study were collected before rhIL-7 administration (day 0) and 4 days after injection. All participants received a single dose of subcutaneous human recombinant IL-7 on day 0 at doses ranging 3--30 μg/kg. Details of the clinical trial (NTC00099671) have been previously published ([@R34]).

Reagents and Antibodies {#S12}
-----------------------

IL-2 (Chiron) was used at 300 U/ml. IL-7 (R&D Systems) was used at 1 nM across most experiments. Purified anti-human CD3 (clone OKT3) and CD28 (clone CD28.2) were used for T cell activation (eBiosciences). CXCL9 and CXCL10 (R&D Systems) were used at 0.1 μM. CXCL12 was used at 50 nM and was kindly provided by Dr. Françoise Baleux (Institut Pasteur). PMA (Sigma-Aldrich) was used at 25 ng/ml. A polyclonal antibody against SAMHD1 phosphorylated at T592 was used for immunoblotting, and a monoclonal antibody conjugated with Alexa Fluor 647 (Life Technologies) was used for flow cytometry. Both antibodies were generated at Institute of Human Genetics. Validation of the murine monoclonal antibody against SAMHD1 phosphorylated at T592 was performed in TH1 cells. Titration of the epitope specificity was performed by preincubation of the antibody with immunizing peptide before incubation on cells (Figure S5A). Phosphorylated SAMHD1 showed a predominant nuclear localization (Figure S5B). Antibody against total SAMHD1 was purchased from Bethyl Laboratories. Dasatinib (Sprycel; Bristol-Meyers Squibb) was kindly provided by Dr. Stephen Mason and Dr. Carey Hwang.

Vectors {#S13}
-------

pLTR-LUC, p3κB-LUC ([@R1]), the pNL4.3-Renilla luciferase replication competent viral clone ([@R15]), pOZ-SAMHD1-WT, and T592 mutant expression vectors ([@R10]) have been previously described.

HIV-1 Infection {#S14}
---------------

Primary CD4+ T cells were infected by spinoculation, as previously described ([@R26]). Luciferase was measured using Renilla Luciferase Assay System (Promega) with a Sirius luminometer (Berthold).

Transfection Assays {#S15}
-------------------

CD4+ T cells were transiently transfected in resting conditions by electroporation at 300 V, 1,500 μF, ∞Ω at a concentration of 20 million per cuvette, 1 μg DNA plasmid per million of cells.

Immunoblotting {#S16}
--------------

Whole protein extracts were fractionated by SDS-PAGE and transferred onto Hybond-ECL nitrocellulose paper (GE Healthcare). Proteins were detected with SuperSignal West Pico Chemiluminescent Substrate (Pierce).

Flow Cytometry Multicolor Assay {#S17}
-------------------------------

Analysis of different CD4+ T cells subsets was performed after staining with anti-CD4-PeCy7 (OKT4; BioLegend), anti-CCR7-FITC (3D12), and anti-CD45RA-PE (HI100; BD Biosciences). Cells were fixed with paraformaldehyde 1%, permeabilized with methanol, and probed with anti-SAMHD1 phosphorylated at T592 conjugated with Alexa Fluor 647. Data acquisition was performed in a fluorescence-activated cell sorting (FACS) Canto flow cytometer (BD Biosciences). Data processing and analysis were done using FACS Diva software and Flowing software v2.5.1.

qPCR {#S18}
----

Strong stop DNA was quantified using primer pairs specific for R and U5 regions of the HIV LTR as described ([@R27]). Episomal forms of 2-LTR and integrated HIV-1 proviral DNA were quantified by conventional and qPCR, respectively, as described ([@R4]). A standard curve of integrated DNA from 8E5 cell line was prepared, and *ccr5* gene was used as housekeeping. Conventional PCR was performed in a C1000 thermal cycler (Bio-Rad), and qPCR was performed in a StepOnePlus Real-Time PCR System, using StepOne v3.2 software (Life Technologies).

Statistical Analysis {#S19}
--------------------

Statistical analysis was performed using Graph Pad Prism 5.0 (Graph Pad Software). Comparisons between two groups were made using two-tailed Mann-Whitney test. Comparisons between more than two groups were made using two-way ANOVA with Bonferroni post test analysis.
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![Kinetics of SAMHD1 Phosphorylation at T592 in Primary CD4+ Lymphocytes in Response to Different Stimuli\
(A) Whole protein extracts from CD4+ T cells treated with anti-CD3/CD28 for 5 consecutive days in the presence or not of IL-2 were analyzed by immunoblotting using a specific antibody against total and phosphorylated (T592) SAMHD1.\
(B) Phosphorylation of SAMHD1 was analyzed by immunoblotting in whole protein extracts from CD4+ T cells treated with IL-2 or IL-7 for 5 consecutive days.\
(C) Analysis by immunoblotting of the effect on SAMHD1 phosphorylation of IL-2 or IL-7 depletion for 48 hr in CD4+ lymphocytes that were previously treated for 5 days.\
(D) Analysis of SAMHD1 phosphorylation by immunoblotting in CD4+ lymphocytes treated with chemokines CXCL12 or CXCL9/10 for 5 days, as well as with IL-2 or IL-7.](nihms820454f1){#F1}

![Effect of IL-2 and IL-7 on Reverse Transcription and Proviral Integration in HIV-Infected Primary CD4+ Lymphocytes\
(A) Analysis by qPCR of the reverse transcription of NL4-3_luciferase strain in CD4+ lymphocytes treated with IL-2 and IL-7 for 5 days and then infected for 5 hr.\
(B and C) The same cells were further cultured for 5 days and then 2-LTRs circles (B) and proviral integration (C) were quantified by qPCR.\
(D) Analysis by qPCR of proviral integration in CD4+ lymphocytes treated with IL-2 or IL-7 for 5 days and then infected with NL4-3_Renilla luciferase infectious strain and incubated for 5 days more in the presence or not of CXCL9 and CXCL10.\
(E) Purified CD4+ T cells were transfected in resting conditions with pOZ-SAMHD1_WT or pOZ-SAMHD1_T592A and then treated with IL-2 or IL-7 for 4 days. Cells were then infected with NL4-3_Renilla and incubated for 48 hr before measuring the synthesis of Renilla (RLUs). One representative experiment is shown.\
Statistical significance was calculated using two-way ANOVA for (A), one-way ANOVA for (B) and (C), and Mann-Whitney t test for (D). \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. All data are represented as mean ± the SEM.](nihms820454f2){#F2}

![IL-7 Induced Mostly Latent Proviral Integration\
(A) Measurement of luciferase production (RLUs) in primary CD4+ T cells treated with IL-2 and IL-7 for 5 days and then infected with NL4-3_Renilla luciferase for 5 days more. PMA was added during the last 18 hr. SAMHD1 levels were analyzed by immunoblotting as described in [Figure 1](#F1){ref-type="fig"}.\
(B) Analysis of luciferase expression in resting CD4+ T cells treated with IL-2 or IL-7 for 5 days and then nucleofected with pLTR-LUC or pκB-LUC vectors. PMA was added 2 hr post-transfection, and cells were incubated for subsequent 18 hr. Statistical significance was calculated using two-way ANOVA. \*\*\*p \< 0.001. Data are represented as mean ± SEM.](nihms820454f3){#F3}

![SAMHD1 Phosphorylation in Different CD4+ T Cell Subsets from HIV-1-Infected Patients Included in the ACTG 5214 Study Who Received a Single Dose of IL-7\
Surface staining with antibodies against CCR7 and CD45RA allowed distributing cells in the different CD4+ T cell subsets (depicted in the upper drawing). Subsequent intracellular staining was performed with an antibody against SAMHD1 phosphorylated at T592. Before-after graphs were depicted for each CD4+ T cell subset. Statistical significance was calculated using Mann-Whitney t test. \*p \< 0.05; ''ns'' for not significant. Data are represented as mean ± SEM. The mean percentages and SEM for SAMHD1 phosphorylation at day 0 and day 4 are shown in the lower table.](nihms820454f4){#F4}

![Cytostatic Drug Dasatinib Interfered with IL-7-Induced SAMHD1 Phosphorylation\
(A) Analysis by immunoblotting of SAMHD1 phosphorylation in CD4+ T cells isolated from healthy donors that were treated with IL-7 for 5 days in the presence of dasatinib.\
(B and C) Viral reverse transcription (B) and proviral integration (C) were analyzed by qPCR in CD4+ T cells treated with IL-7 for 5 days in the presence or not of dasatinib and infected with NL4-3_Renilla luciferase strain for subsequent 5 days.\
(D) Luciferase activity was measured in cell extracts 48 hr after infection.\
Statistical significance was calculated using two-way ANOVA for (B) and Mann-Whitney t test for (C). \*p \< 0.05. Data are represented as mean ± SEM.](nihms820454f5){#F5}

###### Highlights

-   IL-2 and IL-7 induce SAMHD1 phosphorylation, abrogating its antiviral activity

-   IL-7 greatly improves HIV-1 reverse transcription and integration compared to IL-2

-   Dasatinib impedes SAMHD1 phosphorylation and HIV replication caused by IL-2 or IL-7

-   IL-7 and IL-2 help to establish the reservoir, enhancing susceptibility to infection
